Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

Phase I, Open-Label Study To Assess the Safety, Tolerability and Pharmacokinetics of Daily Oral Doses of Cediranib (RECENTIN™;AZD2171) (20, 30 or 45mg) When Co-Administered With Daily Oral Doses of AZD0530 (125mg or 175mg) in Patients With Advanced Solid Tumours

The purpose of the study is to determine if the maximum tolerated doses of AZD2171, in combination with AZD0530, in treating patients with advanced solid tumours are safe, tolerable and efficacious.

Inclusion Criteria:

• Written consent
• Cancer diagnosis & stage
• Patients for whom no standard therapy exists
• World Health Organization (WHO) performance status 0-2
• One or more measurable lesions

Exclusion Criteria:

• Prostate cancer
• Untreated unstable brain or meningeal metastases
• Specific laboratory ranges
• Pregnant or breast-feeding women
• Any evidence of severe or uncontrolled diseases
• Participation in other trials within 30 days